Accueil / Communiqués / IATI Appoints New Co-Chair and Board of Directors

IATI Appoints New Co-Chair and Board of Directors

Sunday, October 28th 2018 at 5:11pm UTC

TEL AVIV, Israel–(BUSINESS WIRE)– IATI, Israel’s umbrella organization of high-tech and life sciences
industries, which includes more than 700 organizations, including
multinationals, mature Israeli companies, venture capital funds,
university and hospital commercialization bodies, incubators and life
science companies, Academics, municipalities and local authorities,
elected this week a new Board of Directors and a new Chairperson.

Erez Zur, Chairman of Infibond who will continue in his position, and
Yaacov Michlin, CEO of Brainsway, were chosen to serve as
co-chairpersons of the union, alongside IATI’s CEO and President, Karin
Meir Rubinstein. Michlin, who represents the life sciences sector, will
replace Yaki Yanai, who has completed a three-year term.

The new Board of Directors consists of 29 key people, 50% of whom are
new, representing all sectors and dimensions of the industry: Prof.
Yossi Matias (Google), Tomer Bar Zeev (IronSoource), Gil Golan (General
Motors), Yuval Tal (Payoneer), Shahar Bar Or (Western Digital), Rafi
Margaliot (Micro Focus), Yahal Zilka (Magma Fund), Jonathan Medved
(OurCrowd), Dr. Yair Schindel (aMoon Fund), Yoram Oron (Vertex), Eyal
Niv (Pitango), Dr. Efrat Shefer (Philips), Tal Levy (Bio-technology
General), Dan Glotter (Optimal Plus), Imad Talhami (Babcom), Racheli
Ganot (Rachip), Alon Aginsky (BlockchainIL), Miriam Shtilman-Lavsovski
(Algotec Systems), Itzik Frid (Takwin Labs), Yonatan Adiri (Healthy.io),
Anat Cohen-Dayag (Compugen), Dr. Eran Eden (MeMed), Prof. Varda Shalev
(Maccabi Tech), Nadav Kidron (Oramed), Elka Nir (Carevature), Yaki Yanai
(Pluristem), Jonatan Berger (The Kitchen), Shlomo Nimrodi (Ramot), Yoram
Tietz (Ernst & Young).

Click for the full list of IATI Board: www.iati.co.il

Karin Meir Rubinstein, IATI CEO and President: « I would like to thank
the previous Board of Directors for their contribution to advancing the
high-tech and life sciences industry in Israel, and to congratulate the
new elected Board of Directors. It is a strong board which reflects all
parts of the industry, and all the relevant fields of innovation today,
including Digital Health, BlockChain and Crypto, and more ».

« As the innovative industries play a more significant role in Israel’s
economy, we face many more challenges. The growth in demand for skilled
workers requires intensive cooperation with regulators and academia in
order to prepare both in the short and long term. Human resources are
Israel’s main resource, and we must continue to work to create and
expand programs to integrate various populations – ultra-Orthodox, Arab
and women – and to allow wider entry into the periphery ».

IATI is the umbrella organization for the hi-tech, life sciences and
other advanced industries in Israel, with hundreds of members paying
from all corners of the industry. IATI connects the technological
ecosystem in Israel, provides solutions and support at various levels,
and integrates the various sectors in the industry for common strategic
and government objectives.

As the umbrella organization of the innovative industries, IATI
cooperates with the relevant public and private organizations in Israel
whose goal is to promote the high-tech and life sciences industry in
Israel. IATI is the most prominent and important representative of the
Israeli high-tech industry vis-a-vis policymakers in the government,
authorities and academia. The Association also provides its members with
a wide range of services, including business development and the
creation of business opportunities, professional seminars and events,
statistical reports, government support and promoting legislation.

Contacts

For IATI
Dana Admoni Rozental, +972-53-606-0061
dana@admonicom.co.il
www.iati.co.il

Source: IATI


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …